Skip to content
Clinical Trials – home

Uniwersytecki Szpital Kliniczny Im.Fryderyka Chopina W Rzeszowie

Verified siteinfo

Poland Ul. Fryderyka Szopena 2, 35-055 Rzeszow, Poland

  • 22 trials recruiting
  • Dermatitis atopic · Psoriasis · Hidradenitis
  • Adults and children

About Specializations

Uniwersytecki Szpital Kliniczny Im.Fryderyka Chopina W Rzeszowie in Rzeszow, Poland specialises in clinical trials of conditions such as Dermatitis atopic, Psoriasis, Hidradenitis, Cutaneous lupus erythematosus, and other specialisations. This site conducts important research.

Main research areas of the site

Dermatology

The medical center is at the forefront of dermatology research, focusing on innovative treatments for various skin conditions. The center's work in this field is characterized by its commitment to improving patient outcomes through cutting-edge therapies.

  • Atopic Dermatitis
  • Hidradenitis Suppurativa
  • Plaque Psoriasis
  • Prurigo Nodularis
  • Vitiligo
  • Acne Vulgaris
  • Bullous Pemphigoid

Through its extensive research, the center is pioneering new approaches to manage and treat these conditions, enhancing the quality of life for patients worldwide.

Oncology

Specializing in oncology, the medical center is dedicated to advancing the treatment of various cancers. Its research is pivotal in developing therapies that target specific cancer types, offering hope to patients with challenging diagnoses.

  • Non-Small Cell Lung Cancer
  • Unresectable Pleural Mesothelioma

The center's innovative research is instrumental in creating more effective and personalized cancer treatments, significantly impacting patient survival rates and quality of life.

Immunology

The center's immunology research is focused on understanding and treating autoimmune and inflammatory diseases. By exploring the immune system's complexities, the center aims to develop therapies that modulate immune responses effectively.

  • Lupus Erythematosus
  • Alopecia Areata
  • Chronic Urticaria

Through its groundbreaking research, the center is contributing to the development of novel treatments that offer relief to patients suffering from these debilitating conditions.

Otolaryngology

In the field of otolaryngology, the medical center is pioneering research into hearing disorders. Its work is crucial in developing treatments that restore hearing and improve auditory health.

  • Idiopathic Sudden Sensorineural Hearing Loss

The center's research is paving the way for innovative therapies that address the underlying causes of hearing loss, offering new hope to patients with auditory impairments.

Nephrology

The center's nephrology research focuses on addressing kidney-related disorders, particularly those affecting protein metabolism. Its work is essential in developing strategies to prevent and treat these conditions.

  • Protein-Energy Wasting in Nephrotic Syndrome

Through its research, the center is advancing the understanding of kidney diseases, leading to improved patient care and management strategies.

Respiratory Medicine

In respiratory medicine, the center is dedicated to improving treatments for lung diseases. Its research is focused on developing therapies that enhance respiratory function and patient outcomes.

  • Electronic Cigarette Cessation

The center's efforts are crucial in addressing the health challenges posed by smoking and vaping, contributing to better respiratory health worldwide.

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Site location
Ul. Fryderyka Szopena 235-055 RzeszowPoland
Recruiting now
22 trials
Conditions studied
30
Partner status
Verified site

More sites in RzeszowPoland

Recruiting now

Ongoing trials

Clinical trials currently enrolling participants at this site.

Condition
Type of trial
Recruitment status
Quick filters

84 clinical trials

Cold urticaria

Recruiting

A study to evaluate the effectiveness of barzolvolimab in participants with cold urticaria and symptomatic dermographism

Registered drug
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Barzolvolimab
  • Sponsor:Celldex Therapeutics Inc.

A study to evaluate the long-term safety and effectiveness of barzolvolimab in patients with chronic spontaneous urticaria

Registered drugNo placebo
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Barzolvolimab
  • Sponsor:Celldex Therapeutics Inc.

Psoriasis

Recruiting

Long-term safety study of deucravacitinib compared to ustekinumab in adults with moderate to severe plaque psoriasis

Registered drugNo placebo
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Deucravacitinib
  • Sponsor:Bristol-Myers Squibb Services Unlimited Company

A Study Testing How Well Bimekizumab Works and How Safe It Is for Adults with Palmoplantar Pustulosis

Registered drug
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Bimekizumab
  • Sponsor:UCB Biopharma

Vitiligo

Recruiting

Study of ruxolitinib cream for children aged 6 to 12 years with non-segmental vitiligo

Investigational
Countries:PolandPoland
  • Participants:0–17 years
  • Substances:Ruxolitinib
  • Sponsor:Incyte Corp.

Vitiligo+2

Recruiting

Long-term safety study of oral povorcitinib in patients with hidradenitis suppurativa, prurigo nodularis, or vitiligo who previously participated in clinical trials

InvestigationalNo placebo
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Povorcitinib
  • Sponsor:Incyte Corp.

Study of VENT-03 tablets in adults with active cutaneous lupus erythematosus with or without systemic lupus erythematosus

Investigational
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:VENT-03
  • Sponsor:Ventus Therapeutics U.S. Inc.

Study on Rituximab for Adults with Relapsing Steroid-Sensitive Nephrotic Syndrome

Registered drugNo placebo
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Rituximab
  • Sponsor:Medical University Of Lodz

Study on Tozorakimab for Patients Hospitalized with Severe Viral Lung Infections Needing Oxygen

Investigational
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Tozorakimab
  • Sponsor:AstraZeneca AB

Study on the Effectiveness of Ketoanalogues in Preventing Muscle Loss in Patients with Nephrotic Syndrome

Registered drugNo placebo
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Keto-Leucine Calcium
  • Sponsor:Agencja Badań Medycznych

Study on Cytisine for Quitting Nicotine E-Cigarettes and Tobacco in Motivated Individuals

Registered drug
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Cytisine
  • Sponsor:University of Rzeszow

Pharmacokinetics, Safety and Efficacy of Nemolizumab in Infants 6–23 Months with Moderate-to-Severe Atopic Dermatitis

InvestigationalNo placebo
Countries:PolandPoland
  • Participants:0–17 years
  • Substances:Nemolizumab
  • Sponsor:Galderma S.A.
Is this your site?

Join our network of research sites

Move up to Verified & featured: your own description, photos and phone number on this page, and top placement on every trial you run.

See the offer for sites
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.